Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomized, Multicenter, Phase III Open-Label study of the efficacy and safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in patients with HER2-Positive locally advanced or metastic breast cancer who have received prior Trastuzumab-based therapy.
Trastuzumab Emtansine
BO21977
NCT00829166
malignant neoplasm of breast
Phase 3
 
January 2015

Powered by ideaPoint, Inc.